CD8A and non-small cell lung carcinoma: CX3CR1 expression is also associated with increased responsiveness to PD-1 checkpoint blockade therapy, as increased expression of CX3CR1 on CD11a+CD8+ T cells in NSCLC patients strongly correlated with a positive clinical response to treatment (164).